It is intended to provide a novel antifeedant. It is also intended to provide an NMU derivative exhibiting a high antifeedant activity even in a common administration form such as peripheral administration. A neuromedin U derivative which contains at least 8 amino acids at the C-terminus of an amino acid sequence of neuromedin U and in which methoxypolyethylene glycol is bound to a polypeptide composed of the same or substantially the same amino acid sequence as that of neuromedin U via a linker having a specific structure.
